Every 8-K that ALLURION TECHNOLOGIES INC (ALUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALUR filings page.
Allurion Technologies, Inc. (ALUR) reports the resignation of two directors and a reduction in board size. On August 17, 2026, Krishna Gupta, a Class I director and member of the Nominating and Corporate Governance Committee, resigned from the board and that committee. On August 19, 2026, Michael Davin, a Class III director, resigned from the board and from his roles as Chairman of the Compensation Committee and member of the Audit Committee. In connection with these departures, the board approved a reduction in its size from five members to three members.
Allurion Technologies, Inc. entered into an exchange agreement with RTW-affiliated stockholders on July 21, 2026, under which they exchanged an aggregate of 392,766 shares of common stock for pre-funded warrants to purchase an equal number of shares. The warrants have a $0.0001 per share exercise price, are immediately exercisable, and include a beneficial ownership limitation initially set at 9.99% of outstanding common stock, adjustable up to 19.99% upon 61 days’ written notice.
Each warrant will automatically terminate upon foreclosure on collateral securing Allurion’s Revenue Interest Financing Agreements or its 6% Convertible Secured Notes due 2031, upon specified bankruptcy events, or at the holder’s election. Affiliates of RTW Investments, LP, which hold these instruments, beneficially owned approximately 38% of Allurion’s outstanding common stock prior to the exchange. Allurion also received notice terminating a November 11, 2025 Securities Purchase and Exchange Agreement that would have exchanged certain indebtedness for Series B Perpetual Convertible Preferred Stock; because closing did not occur by February 28, 2026, the agreement became void with no termination penalty, and the related indebtedness, including amounts under the revenue interest agreements and convertible notes, remains outstanding on its original terms. The exchange relied on the Section 3(a)(9) exemption for transactions with existing security holders.
Allurion Technologies, Inc. stated that Chief Executive Officer and board member Shantanu K. Gaur, M.D. resigned his positions effective immediately on July 17, 2026. The company reported that his resignation was not the result of any disagreement regarding operations, policies or practices.
The board of directors has not appointed an interim or permanent Chief Executive Officer. Chief Operating Officer Ojas Buch is overseeing day-to-day operations and certain responsibilities previously performed by Dr. Gaur, while his title and compensation arrangements remain unchanged.
Allurion Technologies, Inc. reported that director Douglas Hudson, a Class II member of the board, resigned from the board and from the Nominating and Corporate Governance Committee effective June 30, 2026. The company stated that his resignation was not due to any disagreement with management, the board, or company policies or practices. The board is evaluating which current director will be appointed to replace him on the Nominating and Corporate Governance Committee.
Allurion Technologies, Inc. reported that R. Jason Richey, a Class II member of its board of directors, resigned from the board and as chairperson of the Audit Committee on June 24, 2026. The company states that his resignation did not result from any disagreement with management, the board, or any matter relating to operations, policies, or practices. The board is evaluating which of its directors will succeed him as Audit Committee chair.
Allurion Technologies is implementing a 1-for-15 reverse stock split of its common stock to support its plan to regain listing on a national securities exchange such as the NYSE or NYSE American. The split becomes effective at 12:01 a.m. Eastern Time on June 18, 2026, after which every 15 issued or outstanding shares will be combined into one share without changing par value.
This will reduce the number of outstanding shares of common stock from approximately 15,006,253 to approximately 1,000,417, with fractional positions rounded up to the next whole share. The stock will trade on a split-adjusted basis on the OTCQB under the temporary symbol “ALURD” for about 20 trading days before reverting to “ALUR.”
All equity incentive awards, options, RSUs, convertible notes and warrants, including public warrants, will be proportionally adjusted. Each public warrant trading as “ALUR WS” will become exercisable for 0.00378787 shares of common stock at an exercise price of $3,037.50 per share, reflecting the 15-to-1 reverse split ratio.
Allurion Technologies, Inc. reported a change in its external auditor and reiterated previously disclosed weaknesses in its financial controls. The Audit Committee dismissed Deloitte & Touche LLP as independent registered public accounting firm effective May 22, 2026, after Deloitte had audited the company since 2016. Deloitte’s reports on the fiscal years ended December 31, 2024 and 2025 contained no adverse opinions or qualifications, and the company states there were no disagreements with Deloitte on accounting, disclosure, or audit scope.
The company did, however, report material weaknesses in internal control over financial reporting for 2024, 2025 and the interim period through May 22, 2026. These relate to insufficient segregation of duties in the close process, inadequate staffing with public company and technical accounting expertise, and insufficient information systems controls around access and change management. On May 20, 2026, the Audit Committee appointed CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
Allurion Technologies received notice that the New York Stock Exchange will begin proceedings to delist its common stock and warrants after the company failed to meet the NYSE rule requiring an average global market capitalization of at least $15,000,000 over 30 consecutive trading days. Trading on the NYSE was suspended after market close on March 6, 2026, and the shares now trade on the OTCID Market under the same symbols while Allurion appeals the decision.
The company recently obtained U.S. FDA approval for its Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, and has presented the NYSE with a multi-step plan to regain compliance or qualify for listing on NYSE American, strengthen its balance sheet, and fund U.S. commercialization of the Smart Capsule. Management cautions there is no assurance the appeal or relisting efforts will succeed, and notes that liquidity, trading volume and broker quoting on the OTC market may be limited.
Allurion Technologies reported that the New York Stock Exchange plans to begin delisting proceedings because the company no longer meets the NYSE rule requiring at least $50 million in stockholders’ equity or a $50 million average market value. Allurion will appeal this determination to an NYSE board committee, and its common stock and warrants are expected to continue trading on the NYSE during the review period, provided it meets other listing requirements.
The company is pursuing several steps to regain compliance or qualify for listing on another exchange, including capital-raising efforts, negotiations with creditors and security holders, an agreement to exchange all outstanding debt for preferred stock at a premium to the current share price, and a recent warrant inducement transaction. Management warns that there is no assurance the appeal or these initiatives will succeed, and notes that any ultimate delisting could reduce liquidity, pressure the share price, limit access to public capital markets, and weaken its ability to grant equity incentives.
Allurion Technologies entered into a warrant exercise inducement agreement with certain existing warrant holders. The company cut the exercise price of its outstanding warrants to $1.15 per share and the participating holders agreed to exercise warrants for an aggregate 2,659,565 shares of common stock.
In return, Allurion will issue new warrants to these holders to purchase up to 5,319,130 additional shares of common stock at $1.15 per share. The company expects to receive approximately $3.0 million in gross cash proceeds from the warrant exercises. The new warrants will become exercisable after stockholder approval, will expire five years after that date, and are subject to beneficial ownership limits of 4.99% or 9.99% at the holders’ option.
Allurion engaged Roth Capital Partners as financial advisor and will pay a fee equal to 5.0% of the gross proceeds from the warrant exercises, plus up to $40,000 for related expenses. The company also agreed to file a registration statement to cover resale of shares underlying the new warrants within 60 days of the inducement letter.
Allurion Technologies reported that the U.S. Food and Drug Administration granted premarket approval for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, for adults aged 22–65 with obesity and a BMI between 30 and 40 kg/m2 after at least one unsuccessful weight-loss attempt.
The Smart Capsule is swallowed in a brief office visit, forms a gastric balloon that remains in the stomach for about four months, then empties and passes naturally, with the option for a second capsule within a 10‑month treatment period. Allurion estimates this indication provides access to roughly 80 million Americans within the approved BMI range.
The company highlights prior use of the Smart Capsule outside the United States in over 200,000 patients and cites published data showing around 14% total body weight loss with one balloon cycle and over 20% with two cycles or when combined with low‑dose GLP‑1 therapies. Allurion also notes risks around maintaining FDA approval, successful commercialization, and obtaining sufficient financing to continue as a going concern.
Allurion Technologies, Inc. furnished an update on its business by disclosing that it issued a press release with selected preliminary financial results for the quarter and year ended December 31, 2025. The company states that the full text of this press release is provided as Exhibit 99.1 and is incorporated by reference. The information about these preliminary results is being furnished under the rules governing current reports and is expressly described as not being "filed" for liability purposes under the Exchange Act.
Allurion Technologies, Inc. reported the results of its 2025 annual stockholder meeting held on December 18, 2025. Stockholders re-elected three directors — Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey — to serve until the 2028 annual meeting. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Stockholders approved an amended and restated 2023 Stock Option and Incentive Plan that increases the shares authorized for issuance, updates the definition of Fully-Diluted Shares Outstanding, lowers the non-employee director compensation limit, and extends the plan term. They approved repricing certain outstanding stock options under that plan, and authorized issuing common shares upon conversion of Series B Preferred Stock and upon exercise of certain private placement warrants to comply with NYSE listing rules.
Stockholders also approved an amendment to the certificate of incorporation to allow a reverse stock split at a ratio between 1-for-1.5 and 1-for-20, with the exact ratio to be set by the Board. A contingent proposal to adjourn the meeting was not needed because all key proposals received sufficient support.
Allurion Technologies (ALUR) announced two financing moves. The company agreed to a private placement of 2,994,012 common shares with accompanying warrants to purchase up to 2,994,012 shares, for an aggregate purchase price of about $5 million at $1.67 per share and warrant. The warrants are exercisable after stockholder approval at an exercise price of $1.67 and expire five years after approval, with a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election). A resale registration is targeted to be filed by January 10, 2026; Roth Capital Partners will receive a 7% cash fee on gross proceeds and up to $100,000 in expenses.
Separately, Allurion agreed with RTW to exchange its outstanding notes and obligations under two revenue interest financing agreements for newly created Series B convertible preferred stock, subject to stockholder approval no later than January 31, 2026. Each preferred share has a $1,000 stated value, accrues 8.25% dividends, and is convertible at $3.37 per share (subject to adjustment) with a 9.9% beneficial ownership limit. In a related step, on November 4–5, 2025, RTW converted approximately $5 million of notes at the floor conversion price of $3.35, receiving 1,492,539 common shares.
Allurion Technologies, Inc. reported that Milena Alberti-Perez, a Class III director and chairperson of the Audit Committee, resigned from the board effective September 30, 2025. The company states that her resignation was not due to any disagreement with management, the board, or company operations, policies, or practices.
The filing explains that Ms. Alberti-Perez is stepping down to focus on opportunities in the media sector, including a new board role at another public company. Following her departure, the size of Allurion’s board will be reduced from nine to eight members as part of the board’s view that a smaller board can improve efficiency and reduce director compensation costs. The board is evaluating which current director will be appointed as the new Audit Committee chairperson.
Allurion Technologies, Inc. disclosed accounting issues requiring correction and potential amendments to prior SEC reports, noting the company does not expect the corrections to affect reported revenue, gross margin, operating expenses, or cash. The filing flags risks including additional adjustments to prior statements, a delayed Q2 Quarterly Report for the period ended June 30, 2025, possible SEC or regulatory investigations, potential NYSE delisting, and shareholder litigation. The statement frames these as forward-looking risks while the company completes its evaluation.
Allurion Technologies said it issued a press release covering results for the three and six months ended June 30, 2025 and disclosed a potential accounting error. The company identified a likely miscalculation in non-cash items—Other Comprehensive Income (Loss) and Other Income (Expense)—related to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes, and believes correcting those calculations will likely require restating prior-period financial statements. The company stated these adjustments are non-cash and are not expected to affect revenue, gross margin, operating expenses, or cash. The press release is furnished as Exhibit 99.1.